Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05005754
Other study ID # Pro-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date February 28, 2022

Study information

Verified date May 2022
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms. This trial aims to examine its protective effect in humans.


Description:

Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids. However, whether administration of probiotics also has a protective effect in subjects with metabolic syndrome (MetS), who are at high risk for developing atherosclerosis, remain unknown.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date February 28, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - Local residents aged between 30-60 years old; - Stable weight (<5% weight change over last 3 months); - Central obesity defined as waist circumference =90 cm in males or =80 cm in females, Plus any two of the following four conditions i) Elevated triglycerides: serum triglycerides =150 mg/dL (1.7 mmol/L); ii) Reduced HDL cholesterol: serum HDL-c <40 mg/dL (1.03 mmol/L) in males or <50 mg/dL (1.29 mmol/L) in females; iii) Elevated blood pressure: systolic blood pressure =130 mmHg or diastolic blood pressure =85 mmHg; iv) Elevated fasting plasma glucose: fasting plasma glucose =100 mg/dL (5.6 mmol/L) - Absence of any systemic, cardiovascular diseases, as well as infections within the previous month; - Absence of any diet or medication that might interfere with metabolic homoeostasis and gut microbiota, especially antibiotics and probiotics 4 weeks before recruitment. Exclusion Criteria: - Acute illness or current evidence of acute or chronic inflammatory of infective diseases; - Participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment; - Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotics
During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
Placebo control
During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.

Locations

Country Name City State
China Department of Nutrition and Food Hygiene Guangzhou Guangdong
China Sun Yat-Sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Flow-mediated slowing (FMS) FMS is a simple test for endothelial functions measured by Vicorder. In patients whose endothelial function or flow-mediated vasodilation are compromised, the FMS is substantially reduced. from baseline to 12 weeks after intervention
Secondary gut microbiota Alterations of the composition of gut microbiota evaluated by metagenomics from baseline to 12 weeks after intervention
Secondary microbial metabolites alterations of microbial metabolites evaluated by High performance liquid chromatography-mass spectrometry from baseline to 12 weeks after intervention
Secondary Metabolic Syndrome Severity Z Score (MetZ score) MetZ score is an weighted score of the five traditional components of Metabolic syndrome (waist, triglyceride, HDL cholesterol, SBP and fasting glucose). It's used to evaluate the severity of metabolic disorder, and a higher score indicates a more severe status. from baseline to 12 weeks after intervention
Secondary Lipid profiles alterations of blood lipids including total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol determined by automatic biochemical analyser from baseline to 12 weeks after intervention
Secondary Blood pressure alterations of blood pressure from baseline to 12 weeks after intervention
Secondary Insulin sensitivity alterations of HOMA-IR index from baseline to 12 weeks after intervention
See also
  Status Clinical Trial Phase
Recruiting NCT04877548 - Powdered Fermented Fruits for Glycemia Reduction N/A
Completed NCT05995522 - Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity N/A
Completed NCT04021342 - The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function N/A
Recruiting NCT05777746 - The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons With Type 2 Diabetes Mellitus: A Randomized Controlled Trial N/A
Recruiting NCT06358859 - Delta GREENS Food is Medicine Intervention N/A
Completed NCT06201273 - Physical Exercise on Physiological Adaptation Capacity and Chronic Pain in Individuals With Cardiovascular Risk N/A
Recruiting NCT06067009 - Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi) N/A
Recruiting NCT05353322 - Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health N/A
Completed NCT03310242 - Comparison of Sunlight Exposure and Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels N/A
Not yet recruiting NCT05403294 - Impact of New Anthropometric Indices on Outcomes After Cardiac Surgery
Active, not recruiting NCT05071196 - Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide N/A
Completed NCT05687240 - Heart Focused Movement Effects on Cardiometabolic Risk N/A
Not yet recruiting NCT06159556 - Effects of Peanuts on Immunity and Cardiometabolic Risk Factors N/A